Rani Therapeutics Holdings (RANI): Rasio kapitalisasi pasar marang pendapatan
Unique patents for robotic biologic delivery create a powerful technological barrier for Rani Therapeutics (RANI). This price-to-sales chart demonstrates current volatility, where the 9.20 mark captures this metric. The asset's stability currently depends on clinical test results, yet the scaling potential of RaniPill promises high margins due to low-cost automated capsule production.
Rani Therapeutics (RANI) - rincian metrik lan laporan keuangan
- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi bursa:
- indikator kapitalisasi buku:
- statistik kawajiban utang lan likuiditas:
Koefisien Total Utang marang Modal Rani Therapeutics|RANI - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal ranitherapeutics.com|RANI - Gunggung utang perusahaan|Utang marang modal buku Rani Therapeutics Inc|RANI - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Rani Therapeutics|Likuiditas darurat ranitherapeutics.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
RANI - Bathi resik perusahaan|Penghasilan resik sing dikarepake Rani Therapeutics|RANI - Pangali P/E|Pangali Forward P/E ranitherapeutics.com|RANI - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi operasional sadurunge panyusutan Rani Therapeutics Inc|RANI - Bathi operasional EBITDA|Bathi resik saben siji saham sajrone rolas wulan pungkasan Rani Therapeutics|RANI - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan ranitherapeutics.com|RANI - Wutah bathi resik saben saham ing taun iki|Proyeksi tambahing bathi saben saham ing taun ngarep Rani Therapeutics
- data total pendapatan lan volume dodolan:
Ringkesan analitik perusahaan:Rani Therapeutics Holdings
Rani Therapeutics (RANI) focuses on clinical trials of robotic capsules and currently generates no commercial revenue. Due to the absence of sales, the estimated price-to-sales ratio tends toward infinity, reflecting a speculative valuation of future successes. This metric compares the business's market value with its sales volume to determine the asset's premium. Analysis based on the estimated price-to-sales ratio allows for the timely detection of a dangerous gap between capitalization and actual cash flows.
Perusahaan pesaing
HLN (haleon.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Kenvue KVUE|Rasio kapitalisasi pasar marang pendapatan VRNA|Jyong Biotech Corp - Multiplikator P/S|LGND - Multiplikator P/S|Amneal Pharmaceuticals (AMRX) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan PRGO|ALVO (Alvotech SA) - Multiplikator P/S|Liquidia Corp (LQDA) - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan GLPG (Galapagos Genomics)|ANIP (ANI Pharmaceuticals Corp) - Rasio kapitalisasi pasar marang pendapatan|MannKind Corporation - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan AMPH (amphastar.com)|Pacira BioSciences, Inc. - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan SPRY (ARS Pharmaceuticals Inc)|TBPH: Multiplikator P/S|Rega marang dodolan Aquestive Corp (AQST)|Rasio rega marang pendapatan scPharmaceuticals, Inc.|TECX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S TNXP|Multiplikator P/S sxtchina.com (SXTC)|Rasio rega marang pendapatan Eupraxia Pharmaceuticals Inc. EPRX|BHST (BioHarvest Sciences Inc) - Rasio rega marang dodolan|eXoZymes Inc - Multiplikator P/S|Rega marang dodolan Oramed Pharmaceuticals|ENTX (enterabio.com) - Kapitalisasi marang pendapatan|MindWalk Holdings, Inc. (HYFT) - Multiplikator P/S|Kapitalisasi marang pendapatan ABVC|CPIX (Cumberland Corp) - Kapitalisasi marang volume dodolan|Multiplikator P/S QNTM|Koefisien rega marang pendapatan fibrogen.com|Multiplikator P/S TELO (Telomir Pharmaceuticals, Inc.)|SNYR - Kapitalisasi marang pendapatan|RLYB - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Lexaria Bioscience LEXX|Pulmatrix, Inc. (PULM) - Rasio rega marang pendapatan|Pheton Holdings - Rasio kapitalisasi pasar marang pendapatan|APM (Aptorum Group Ltd) - Multiplikator P/S|Multiplikator P/S Lyra Therapeutics Inc.|Rasio rega marang pendapatan Impact BioMedical (IBO)|tnfpharma.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S YCBD (cbdMD)|Koefisien rega marang pendapatan painreform.com (PRFX)|CYTO - Rasio rega marang pendapatan|Rasio rega marang dodolan LIPO|OPTN: Multiplikator P/S|Pieris Pharma - Rasio kapitalisasi pasar marang pendapatan|PROC (Procaps Group S.A.) - Multiplikator P/S|Multiplikator P/S petrospharma.com|Rasio rega marang pendapatan Qilian International Holding (QLI)|SLRN (Acelyrin Inc.) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan TFF Pharma TFFP
